News articles about Strongbridge Biopharma (NASDAQ:SBBP) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Strongbridge Biopharma earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.0338659217663 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- $3.25 Million in Sales Expected for Strongbridge Biopharma (SBBP) This Quarter (americanbankingnews.com)
- -$0.41 Earnings Per Share Expected for Strongbridge Biopharma (SBBP) This Quarter (americanbankingnews.com)
- Strongbridge Biopharma (SBBP) Upgraded to Hold by Zacks Investment Research (americanbankingnews.com)
- Strongbridge Biopharma (SBBP) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Global Genes® Partners with University of Pennsylvania Orphan Disease Center for 2018 RARE Patient Advocacy … (markets.businessinsider.com)
A number of equities research analysts recently issued reports on SBBP shares. Cantor Fitzgerald set a $14.00 price target on shares of Strongbridge Biopharma and gave the company a “buy” rating in a research note on Thursday, April 5th. BidaskClub downgraded shares of Strongbridge Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 4th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research note on Thursday, January 18th. Finally, Zacks Investment Research downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.81.
Strongbridge Biopharma (NASDAQ:SBBP) last announced its earnings results on Monday, March 12th. The biotechnology company reported ($0.34) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34). The firm had revenue of $2.98 million during the quarter, compared to analysts’ expectations of $2.98 million. equities research analysts predict that Strongbridge Biopharma will post -1.52 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Strongbridge Biopharma (SBBP) Share Price” was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://weekherald.com/2018/04/18/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-strongbridge-biopharma-sbbp-share-price.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.